In this setting, GNAS mutations, known to lead to elevated intracellular cAMP levels and activation of downstream dependent pathways,[1] open new clinical insights on IPMN. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.